WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
FONR
FONAR CORP
United States
$112.94M6,710,80747.70%3.51%
STRR
STAR EQUITY HOLDINGS INC
United States
$14.03M15,848,2023.66%96.34%Net BuyingNet Selling
ICLR
ICON PLC
Ireland
$24.68B82,495,08695.64%0.00%
IDXX
IDEXX LABORATORIES INC
United States
$40.82B83,089,38187.71%1.68%Net SellingNet Selling
RVTY
REVVITY INC
United States
$12.64B123,529,82186.51%2.53%Net BuyingNet Buying
NEOG
NEOGEN CORP
United States
$2.60B216,607,74698.57%1.43%Net BuyingNet Buying
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
United States
$12.11B51,349,77096.79%3.21%Net SellingNet Selling
TMO
THERMO FISHER SCIENTIFIC INC
United States
$212.72B381,312,26889.26%0.87%Net SellingNet Selling
QGEN
QIAGEN NV
Netherlands
$9.05B228,202,75561.40%0.00%
SHC
SOTERA HEALTH CO
United States
$3.11B282,832,20061.96%38.04%Net SellingNet Selling
ENZ
ENZO BIOCHEM INC
United States
$59.42M51,225,73431.93%48.12%Net Selling
A
AGILENT TECHNOLOGIES INC
United States
$41.09B293,055,28487.43%1.18%Net BuyingNet Selling
LH
LABORATORY CORP OF AMERICA HOLDINGS
United States
$17.10B84,100,00095.77%1.52%Net SellingNet Selling
MEDP
MEDPACE HOLDINGS INC
United States
$11.91B30,759,28127.34%72.66%Net SellingNet Selling
DHR
DANAHER CORP
United States
$177.28B739,701,72575.94%24.06%Net BuyingNet Selling
CSTL
CASTLE BIOSCIENCES INC
United States
$527.86M27,449,98384.17%15.83%Net SellingNet Selling
TWST
TWIST BIOSCIENCE CORP
United States
$1.69B57,818,02288.25%11.75%Net SellingNet Selling
DGX
QUEST DIAGNOSTICS INC
United States
$14.24B110,707,29388.06%1.77%Net SellingNet Selling
WAT
WATERS CORP
United States
$18.92B59,202,62692.46%7.54%Net SellingNet Selling
MTD
METTLER TOLEDO INTERNATIONAL INC
United States
$26.71B21,478,70594.58%4.52%Net SellingNet Buying
XGN
EXAGEN INC
United States
$24.65M17,235,75136.96%63.04%Net SellingNet Selling
SERA
SERA PROGNOSTICS INC
United States
$325.55M32,425,66134.04%21.12%Net SellingNet Selling
IQV
IQVIA HOLDINGS INC
United States
$41.96B181,500,00053.95%46.05%Net SellingNet Selling
NTRA
NATERA INC
United States
$10.92B120,757,87778.38%21.62%Net SellingNet Selling
PSNL
PERSONALIS INC
United States
$63.63M50,503,88943.52%18.39%Net SellingNet Buying
EXAS
EXACT SCIENCES CORP
United States
$11.86B181,530,96788.62%3.40%Net SellingNet Selling
PRPO
PRECIPIO INC
United States
$9.63M1,430,2920.61%99.39%
OLK
OLINK HOLDING AB (PUBL)
Sweden
$2.83B124,342,71530.18%0.00%
DRIO
DARIOHEALTH CORP
Israel
$33.56M29,442,53229.42%53.98%
ACRS
ACLARIS THERAPEUTICS INC
United States
$85.82M70,925,04256.85%43.15%Net SellingNet Selling
FLGT
FULGENT GENETICS INC
United States
$618.03M29,784,77148.02%42.49%Net SellingNet Selling
STIM
NEURONETICS INC
United States
$123.79M29,756,05350.13%49.87%Net SellingNet Selling
DMTK
DERMTECH INC
United States
$21.47M34,623,44315.75%77.74%Net SellingNet Selling
GH
GUARDANT HEALTH INC
United States
$2.08B121,712,72464.42%35.58%Net SellingNet Selling
NEO
NEOGENOMICS INC
United States
$1.75B127,610,03972.39%27.61%Net SellingNet Selling
BGLC
BIONEXUS GENE LAB CORP
Malaysia
$10.99M17,667,6630.59%97.91%
BNR
BURNING ROCK BIOTECH LTD
China
$81.92M102,396,20819.66%0.00%
RDNT
RADNET INC
United States
$3.27B68,475,44364.36%35.64%Net Selling
LAB
STANDARD BIOTOOLS INC
United States
$803.63M290,117,93016.74%33.34%Net BuyingNet Buying
APDN
APPLIED DNA SCIENCES INC
United States
$6.11M16,978,7039.45%72.88%
PRE
PRENETICS GLOBAL LTD
Hong Kong
$42.28M12,114,92210.11%0.00%
CDNA
CAREDX INC
United States
$424.58M51,778,52379.47%20.53%Net SellingNet Selling
BDSX
BIODESIX INC
United States
$121.18M96,942,06117.45%72.27%Net BuyingNet Selling
MDXH
MDXHEALTH SA
Belgium
$6.35M27,038,09411.79%88.21%
NDRA
ENDRA LIFE SCIENCES INC
United States
$2.89M11,035,6591.19%8.73%Net Buying
CHEK
CHECK-CAP LTD
Israel
$12.75M5,849,7561.07%0.00%
ME
23ANDME HOLDING CO
United States
$194.13M482,916,63627.87%2.59%Net BuyingNet Selling
XWEL
XWELL INC
United States
$5.73M4,179,6311.65%98.35%Net Buying
ULS
UL SOLUTIONS INC
United States
N/A200,000,0000.00%0.00%
PRPH
PROPHASE LABS INC
United States
$111.07M18,045,2099.36%57.17%
AWH
ASPIRA WOMEN's HEALTH INC
United States
$41.85M12,344,1040.84%99.16%Net Buying
OPK
OPKO HEALTH INC
United States
$857.30M696,991,66717.43%82.57%Net BuyingNet Buying
NOTV
INOTIV INC
United States
$145.20M25,790,68018.17%43.71%Net Buying
VNRX
VOLITIONRX LTD
United States
$55.72M82,068,4427.76%40.12%Net Buying
GENE
GENETIC TECHNOLOGIES LTD
Australia
$754.83k115,417,2460.02%0.00%
MYGN
MYRIAD GENETICS INC
United States
$1.72B89,874,88692.31%7.69%Net SellingNet Selling
ISPC
ISPECIMEN INC
United States
$1.92M9,087,4674.31%71.05%Net Buying
BIAF
BIOAFFINITY TECHNOLOGIES INC
United States
$31.78M11,514,3541.36%36.42%Net BuyingNet Buying
PMD
PSYCHEMEDICS CORP
United States
$15.22M5,742,76122.46%50.15%Net Selling
ILMN
ILLUMINA INC
United States
$19.25B158,900,00089.29%1.97%Net SellingNet Buying
OCX
ONCOCYTE CORP
United States
$20.90M8,260,7623.66%96.34%Net BuyingNet Buying
MYNZ
MAINZ BIOMED NV
Germany
$20.74M21,165,4821.10%0.00%
TRIB
TRINITY BIOTECH PLC
Ireland
$14.64M153,310,2803.93%0.00%
MMA
ALTA GLOBAL GROUP LTD
Australia
N/A10,223,0790.00%0.00%
CNTG
CENTOGENE NV
Germany
$13.52M27,595,8359.75%0.00%
TTOO
T2 BIOSYSTEMS INC
United States
$16.37M5,512,3320.56%99.44%Net Selling

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.89% over the past year, overperforming other diagnostic & research stocks by 11 percentage points.

2. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 2.03% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 18.87% from Idexx Laboratories's current stock price of $491.29.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 39.8% over the past year, overperforming other diagnostic & research stocks by 47 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 15.82% from Icon's current stock price of $299.12.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.23%, which is 2 percentage points higher than the diagnostic & research industry average of 1.39%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.24%, which is 1 percentage points higher than the diagnostic & research industry average of 1.39%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.42%, which is the same as the diagnostic & research industry average of 1.39%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.61% in the last day, and down -4.74% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 9.26% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -54.51% in the past year. It has underperformed other stocks in the diagnostic & research industry by -47 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 3.89% in the past year. It has overperformed other stocks in the diagnostic & research industry by 11 percentage points.

Are diagnostic & research stocks a good buy now?

47.83% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 9.37% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.95x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.